Raymond Anderson Sells 3,142 Shares of Monopar Therapeutics (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the sale, the director owned 23,751 shares of the company’s stock, valued at approximately $2,654,649.27. The trade was a 11.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Up 0.2%

MNPR traded up $0.22 during trading on Thursday, hitting $113.94. The company’s stock had a trading volume of 142,825 shares, compared to its average volume of 220,179. The firm has a market capitalization of $764.77 million, a P/E ratio of -52.51 and a beta of 1.47. Monopar Therapeutics Inc. has a twelve month low of $32.77 and a twelve month high of $124.82. The stock’s fifty day moving average price is $104.63 and its 200-day moving average price is $74.34.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02. Equities research analysts expect that Monopar Therapeutics Inc. will post -2.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MNPR. California State Teachers Retirement System grew its holdings in Monopar Therapeutics by 2,224.3% during the second quarter. California State Teachers Retirement System now owns 5,741 shares of the company’s stock worth $532,000 after buying an additional 5,494 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Monopar Therapeutics during the 2nd quarter valued at $7,124,000. Bank of America Corp DE lifted its stake in Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after acquiring an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC boosted its holdings in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after acquiring an additional 30,370 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in Monopar Therapeutics during the 1st quarter worth $250,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday, July 17th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Zacks Research downgraded Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Finally, Cantor Fitzgerald lowered Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $109.00 to $119.00 in a research report on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.67.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.